Welcome to our dedicated page for Tenon Medical news (Ticker: TNON), a resource for investors and traders seeking the latest updates and insights on Tenon Medical stock.
Tenon Medical, Inc. (TNON) delivers innovative solutions for sacroiliac joint disorders through its Catamaran™ System. This page provides authorized updates on clinical advancements, regulatory milestones, and strategic developments directly from the company and verified sources.
Investors and medical professionals will find comprehensive coverage of FDA clearances, peer-reviewed study results, and partnership announcements. Our curated news collection features earnings reports, product launch details, and analysis of market expansion efforts in minimally invasive spine technology.
Key updates include progress in post-market clinical studies, intellectual property developments, and educational initiatives for surgeons. All content undergoes strict verification to ensure alignment with financial disclosure regulations and medical accuracy standards.
Bookmark this page for real-time updates on TNON's pioneering work in SI joint fusion technology. For direct access to corporate filings and investor resources, visit the official Tenon Medical website through our verified links.
Tenon Medical (NASDAQ:TNON), a company focused on treating sacroiliac joint disorders, has announced the timing of its second quarter 2024 financial results. The company will release its financial results for the quarter ended June 30, 2024, after market close on Tuesday, August 13, 2024. This will be followed by a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results in detail and conduct a Q&A session with covering analysts. Investors can join the call via phone or webcast, with dial-in numbers provided for both domestic and international participants. An audio replay will be available until August 27, 2024, through Tenon's Investor Relations website or via telephone.
Tenon Medical (NASDAQ:TNON) reported significant growth in its Q1 2024 financial results, showcasing a 66% year-over-year revenue increase to $719,000, driven by a 42% rise in Catamaran System surgical procedures.
The company achieved a gross profit of $470,000, marking a stark improvement from a gross loss of ($47,000) in Q1 2023, with a stable gross margin of 65%.
Notable developments include positive fusion results from a post-market study of the Catamaran SI Joint Fusion System and the receipt of a U.S. patent allowance for its Catamaran implant.
The company reduced its operating losses to $3.5 million, down from $4.9 million in Q1 2023, and ended the quarter with $4.4 million in cash and cash equivalents.
Additionally, Tenon retired $1.25 million in debt through a $2.6 million Series A Preferred Stock financing.
Tenon Medical, Inc. will announce its first quarter 2024 financial results on May 14, 2024, after market close. The company will host a conference call to discuss the results in detail, followed by a Q&A session with analysts. Investors can access the call via dial-in or webcast and listen to the playback on the Investor Relations website.
FAQ
What is the current stock price of Tenon Medical (TNON)?
What is the market cap of Tenon Medical (TNON)?
